EYEPOINT INC (EYPT)
Sector: Health Care
2026 Annual Meeting Analysis
EYEPOINT INC · Meeting: June 18, 2026
Directors FOR
8
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Eight Directors
Director since 2018 with extensive pharma leadership experience; EYPT's 3-year price return of +51.1% is strong positive, and the gap versus XBI (the SPDR S&P Biotech ETF) is only -15.7pp, well below the 65pp threshold required to trigger an against vote; no overboarding, independence, or attendance concerns.
Executive director serving as President and CEO since July 2023; EYPT's 3-year price return of +51.1% is strong positive, and the gap versus XBI (the SPDR S&P Biotech ETF) is only -15.7pp, well below the 65pp threshold required to trigger an against vote; no overboarding or attendance concerns.
Director since 2018 with deep pharmaceutical sciences expertise; EYPT's 3-year price return of +51.1% is strong positive, and the gap versus XBI (the SPDR S&P Biotech ETF) is only -15.7pp, well below the 65pp threshold; classified as non-independent due to prior consulting fees but does not serve on audit or compensation committee.
Director since 2019; serves as Audit Committee Chair and is a licensed CPA with extensive CFO experience in life sciences, satisfying financial expertise requirements; EYPT's 3-year return gap versus XBI (the SPDR S&P Biotech ETF) of -15.7pp is well below the 65pp trigger threshold.
Director since 2022 with over 35 years of biopharma and medical device experience including CEO tenure at a public company; EYPT's 3-year return gap versus XBI (the SPDR S&P Biotech ETF) of -15.7pp is well below the 65pp trigger threshold; no overboarding or attendance concerns.
Director since 2023; experienced financial executive with over 30 years in healthcare investment banking; joined within approximately 3 years so tenure overlaps a portion of the measurement period, but the gap versus XBI (the SPDR S&P Biotech ETF) of -15.7pp does not approach the 65pp trigger threshold; serves on Audit Committee with demonstrable financial expertise.
Director since 2024; extensive pharma CEO and chairman experience; joined within the past 24 months and is therefore exempt from the TSR trigger under the new-director exemption; no overboarding or attendance concerns noted.
Director since 2025; prominent retinal specialist with directly relevant clinical expertise for EyePoint's pipeline; joined within the past 24 months and is therefore exempt from the TSR trigger under the new-director exemption; no overboarding or attendance concerns noted.
All eight director nominees receive a FOR vote. EyePoint's 3-year price return of +51.1% is firmly in the strong-positive tier, and the underperformance gap versus XBI (the SPDR S&P Biotech ETF) of -15.7pp is far below the 65pp threshold required to trigger an against vote for any director. No overboarding, attendance, independence-on-committee, or familial relationship concerns were identified across the slate.
Say on Pay
✓ FORCEO
Jay Duker
Total Comp
$5,568,352
Prior Support
N/A
CEO Jay Duker's total compensation was approximately $5.57 million for 2025, which is reasonable for a clinical-stage biotech CEO at a $1.1 billion market cap company overseeing two pivotal Phase 3 trials. The pay mix is heavily weighted toward variable and performance-based compensation — base salary of $696,251 represents only about 12.5% of total pay, well under the 40% fixed-pay threshold, with the remainder in stock awards, option awards, and a performance cash bonus that was tied to measurable clinical and operational milestones scored at 150% of target. EyePoint's 1-year stock return of +113.5% and 3-year return of +51.1% demonstrate strong alignment between above-target incentive payouts and shareholder outcomes, and the company maintains a Dodd-Frank compliant clawback policy.
Auditor Ratification
✓ FORAuditor
Deloitte & Touche LLP
Tenure
N/A
Audit Fees
$977,000
Non-Audit Fees
$215,000
Non-audit fees (tax fees of $213,000 plus other fees of $2,000 = $215,000) represent approximately 22% of audit fees ($977,000), well below the 50% threshold that would raise independence concerns. Deloitte is a Big 4 firm appropriate for a company of EyePoint's size. Auditor tenure is not disclosed in the proxy, so the tenure trigger does not fire per policy. No material restatements were identified.
Overall Assessment
EyePoint's 2026 annual meeting presents a clean ballot with no significant governance concerns: the full director slate passes the TSR screen against XBI (the SPDR S&P Biotech ETF) given strong positive absolute returns and a gap well below the 65pp trigger threshold, Deloitte's non-audit fee ratio of approximately 22% is well within acceptable limits, and the CEO pay program demonstrates strong pay-for-performance alignment with a heavily variable compensation structure tied to clinical milestones and supported by a 113.5% one-year stock return. All standard proposals — director elections, Say on Pay, and auditor ratification — receive a FOR vote determination; the equity plan share increase (Proposal 2) is outside current policy scope.